Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00046787
Status:
COMPLETED
Last Update Posted:
2011-10-20
First Post:
2002-10-03
Brief Title:
Efficacy and Safety Study of OSI-211 Liposomal Lurtotecan to Treat Recurrent Small Cell Lung Cancer
Sponsor:
Astellas Pharma Inc
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
Phase II Study to Determine the Efficacy of OSI-211 Liposomal Lurtotecan Given on Days 1 2 3 Every 3 Weeks in Patients With Recurrent Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2011-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether OSI-211 Liposomal Lurtotecan is an effective and safe treatment for patients with recurrent small cell lung cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None